Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent

NCT05622162 is registered in ClinicalTrials.gov with ITEL Telecomunicazioni Srl as lead sponsor.

NCT NCT05622162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05622162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Multicentre Prospective Comparative Study of Detection Rate of 18F-JK-PSMA-7 and of 18F-fluorocholine in Patients With Biochemical Recurrence of Prostate Cancer After Previous Treatment With Curative Intent
Lead sponsor
ITEL Telecomunicazioni Srl
Phase
Phase 3
Overall status
Unknown status
Start date
December 19, 2022
Completion date
June 30, 2024
Enrollment
106 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

18f- fluorocholine, prostate cancer, prostatectomy, psma pet, radiotherapy, tumor of prostate